Outlook Therapeutics (OTLK) Income towards Parent Company: 2015-2020
Historic Income towards Parent Company for Outlook Therapeutics (OTLK) over the last 6 years, with Sep 2020 value amounting to -$9.9 million.
- Outlook Therapeutics' Income towards Parent Company rose 1.73% to -$9.9 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$38.3 million, marking a year-over-year decrease of 11.00%. This contributed to the annual value of -$75.4 million for FY2024, which is 27.78% down from last year.
- As of Q3 2020, Outlook Therapeutics' Income towards Parent Company stood at -$9.9 million, which was down 229.09% from -$3.0 million recorded in Q2 2020.
- Outlook Therapeutics' 5-year Income towards Parent Company high stood at -$1.9 million for Q4 2017, and its period low was -$22.3 million during Q2 2016.
- Over the past 3 years, Outlook Therapeutics' median Income towards Parent Company value was -$9.7 million (recorded in 2018), while the average stood at -$9.2 million.
- In the last 5 years, Outlook Therapeutics' Income towards Parent Company spiked by 89.94% in 2017 and then tumbled by 407.26% in 2018.
- Outlook Therapeutics' Income towards Parent Company (Quarterly) stood at -$19.1 million in 2016, then soared by 89.94% to -$1.9 million in 2017, then plummeted by 407.26% to -$9.7 million in 2018, then increased by 9.86% to -$8.8 million in 2019, then rose by 1.73% to -$9.9 million in 2020.
- Its last three reported values are -$9.9 million in Q3 2020, -$3.0 million for Q2 2020, and -$16.6 million during Q1 2020.